Repare shares jump 20.13% intraday after Gilead acquires RP-3467 for up to $30 million in asset deal.

Repare Therapeutics (RPTX) surged 20.13% intraday following the announcement of a $30 million asset purchase agreement with Gilead Sciences for its Polθ ATPase inhibitor, RP-3467. The upfront $25 million payment increased Repare’s cash reserves, boosting the estimated per-share payment in its pending acquisition by XenoTherapeutics to $2.20 from prior projections. This dual transaction—securing immediate proceeds and enhancing shareholder value in the Xeno deal—driven by Gilead’s interest in RP-3467’s potential as a best-in-class oncology candidate, fueled investor optimism. The intraday rally reflects confidence in the strategic exits of key assets and the improved liquidity profile, aligning with the company’s focus on maximizing returns for shareholders amid its impending merger.